{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:25:06Z","timestamp":1757701506930,"version":"3.32.0"},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":2191,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:p>Objective: To describe patients with fungal infections in whom drug interactions and bioavailability problems were associated with itraconazole treatment failure.<\/jats:p><jats:p>Design: Retrospective chart review.<\/jats:p><jats:p>Setting: Two tertiary care university\u2010affiliated teaching hospitals.<\/jats:p><jats:p>Population Studied: Itraconazole\u2010treated patients between 1990 and 1992.<\/jats:p><jats:p>Main Results: Four patients treated with itraconazole were identified in whom suboptimal serum itraconazole levels were associated with relapse of disseminated histoplasmosis, treatment failure of invasive aspergillosis or development of superficial mycoses. Low serum itraconazole levels were associated with concurrent therapy with rifampin or agents inhibiting gastric acid secretion, with administration of itraconazole capsule contents through a nasogastric tube or with the presence of <jats:sc>aids<\/jats:sc>.<\/jats:p><jats:p>Conclusions: It is recommended that serum itraconazole levels be measured in patients with potentially life\u2010threatening mycoses if coexistent factors may interfere with itraconazole therapy.<\/jats:p>","DOI":"10.1155\/1994\/612027","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T08:00:29Z","timestamp":1458028829000},"page":"179-183","source":"Crossref","is-referenced-by-count":4,"title":["Itraconazole: Precautions Regarding Drug Interactions and Bioavailability"],"prefix":"10.1155","volume":"5","author":[{"given":"Michael PE","family":"Puttick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1994,2]]},"container-title":["Canadian Journal of Infectious Diseases and Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjidmm\/1994\/612027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/1994\/612027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T05:02:42Z","timestamp":1735621362000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/1994\/612027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1155\/1994\/612027"],"URL":"https:\/\/doi.org\/10.1155\/1994\/612027","archive":["Portico"],"relation":{},"ISSN":["1712-9532","1918-1493"],"issn-type":[{"type":"print","value":"1712-9532"},{"type":"electronic","value":"1918-1493"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}